Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Bayer Pharma will pay Trius Therapeutics $25 million up front for regional rights to torezolid, an antibiotic against gram-positive bacteria that is in Phase III trials to treat acute bacterial skin and skin structure infections (ABSSSI). The San Diego-based firm will allow Bayer to develop the antibiotic in Africa, Latin America, the Middle East, and Asia excluding North and South Korea. Bayer will pay 25% of the costs necessary to gain approval for torezolid as a treatment for ABSSSI and pneumonia, and potentially pay up to $69 million more in milestones.
This article has been sent to the following recipient: